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Skeletal muscleIn contrast to urodele amphibians and teleost ﬁsh, mammals lack the regenerative responses to replace large
body parts. Amphibian and ﬁsh regeneration uses dedifferentiation, i.e., reversal of differentiated state, as a
means to produce progenitor cells to eventually replace damaged tissues. Therefore, induced activation of dedif-
ferentiation responses in mammalian tissues holds an immense promise for regenerative medicine. Here we
demonstrate that ectopic expression ofMsx2 in cultured mouse myotubes recapitulates several aspects of am-
phibian muscle dedifferentiation. We found that MSX2, but not MSX1, leads to cellularization of myotubes and
downregulates the expression of myotube markers, such as MHC, MRF4 and myogenin. RNA sequencing of
myotubes ectopically expressingMsx2 showed downregulation of over 500 myotube-enriched transcripts and
upregulation of over 300 myoblast-enriched transcripts. MSX2 selectively downregulated expression of Ptgs2
and Ptger4, two members of the prostaglandin pathway with important roles in myoblast fusion during muscle
differentiation. Ectopic expression ofMsx2, aswell asMsx1, induced partial cell cycle re-entry ofmyotubes by up-
regulating CyclinD1 expression but failed to initiate S-phase. Finally, MSX2-induced dedifferentiation in mouse
myotubes could be recapitulated by a pharmacological treatmentwith trichostatin A (TSA), bonemorphogenetic
protein 4 (BMP4) and ﬁbroblast growth factor 1 (FGF1). Together, these observations indicate that MSX2 is a
major driver of dedifferentiation in mammalian muscle cells.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The induction of cellular plasticity has emerged as a powerful tool for
regenerative medicine (Yamanaka and Blau, 2010; Nie et al., 2012;
Katsuyama and Paro, 2011). Regeneration seen in a wide range of
non-mammalian vertebrates, such as urodele amphibians and teleost
ﬁsh provides important information about natural mechanisms of
using cellular plasticity for renewing large body parts (Brockes and
Kumar, 2002; Gemberling et al., 2013). A crucial question for the ﬁeldomain) homeobox homolog 2;
chain; Mrf4, muscle regulatory
tger4, prostaglandin E receptor
ein 4; FGF1, ﬁbroblast growth
ion Omnibus (GEO): GSE65619
=sbibegcmzjudhep&acc=GS
s Science and Engineering (D-
and.
ato.paro@bsse.ethz.ch (R. Paro).
. This is an open access article underof regenerative medicine is whether urodele regeneration can be reca-
pitulated in mammalian cells.
Studies on amphibian or ﬁsh regeneration identiﬁed reversal and
plasticity of the differentiated state as a major mechanism to produce
stem cell-like cells during regeneration (Jopling et al., 2010; Echeverri
et al., 2001; Kragl et al., 2009). This process, classically called dedifferen-
tiation, reprograms differentiated cells at the wound site back to a pro-
genitor stage, which can then proliferate and replace the missing tissue
with appropriate patterning (Stoick-Cooper et al., 2007). Dedifferentia-
tion has been best characterized in salamander muscle cells. It has been
shown that upon signals produced in the regenerating tissue, multinu-
cleated postmitotic differentiatedmyotubes can reverse their differenti-
ated state and give rise to proliferating progenitors (Lo et al., 1993;
Kumar et al., 2000; Sandoval-Guzmán et al., 2014). To date, there is
not any convincing evidence demonstrating dedifferentiation occurring
physiologically in mammalian muscles. Therefore, an intriguing ques-
tion is whether this process could be engineered into mammalian
muscle.
Mammalian muscle differentiation is governed by the expression of
a series of master regulatory transcription factors, collectively calledthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
543A. Yilmaz et al. / Stem Cell Research 15 (2015) 542–553myogenic regulatory factors (MRFs) (Bentzinger et al., 2012; Molkentin
and Olson, 1996). Proliferating myoblasts start expressing MRFs, i.e.
MyoD, myogenin, MRF4 and MYF5, in an orderly fashion, withdraw
from cell cycle and fuse to each other to form multinucleated
postmitotic myotubes (Perry and Rudnick, 2000). Differentiated
myotubes express structural proteins such as MHC and exhibit mus-
cle-speciﬁc structural properties (Bentzinger et al., 2012). Due to their
multinucleated morphology and their postmitotic differentiated states,
myotubes have to reverse several processes to dedifferentiate. The
steps that myotubes have to go through for dedifferentiation are: 1)
phenotypic dedifferentiation (loss of differentiated muscle-speciﬁc
markers) 2) cellularization (fragmentation of multinucleated myotubes
intomononucleated cells) and 3) cell cycle re-entry (Duckmanton et al.,
2005). Previous studies in newts and mammals have identiﬁed several
cell cycle regulators or transcription factors regulating muscle dediffer-
entiation (Echeverri and Tanaka, 2002; Tanaka et al., 1999; McGann et
al., 2001; Odelberg et al., 2000; Kumar et al., 2004; Pajcini et al., 2010;
Tanaka et al., 1997; Lööf et al., 2007). Among these factors, the
homeodomain-containing transcription factor,MSX1, has been attribut-
ed a master regulatory role in amphibian myotube dedifferentiation
(Duckmanton et al., 2005; Kumar et al., 2004). Two studies also showed
that MSX1 leads to dedifferentiation of mammalian myotubes
(Odelberg et al., 2000; Yang et al., 2014). However, expression of the
MSX1 homolog, MSX2, during amphibian regeneration precedes
MSX1 expression andMSX2 is highly expressed at the early regenerates
(Echeverri and Tanaka, 2002; Carlson et al., 1998). Despite this temporal
importance in animals, the potential role of MSX2 in dedifferentiation
was previously not addressed in salamander or mammalian muscle
cells.
We sought to test the potential role of MSX2 during muscle cell de-
differentiation by ectopically expressing it in culturedmousemyotubes.
We found that ectopic expression of Msx2 leads to dedifferentiation
with partial cell cycle re-entry in postmitotic multinucleated mammali-
an muscle cells and this response can be recapitulated by a pharmaco-
logical treatment with trichostatin a (TSA), bone morphogenetic
protein 4 (BMP4) and ﬁbroblast growth factor 1 (FGF1).
2. Materials and methods
2.1. Antibodies and materials
Anti-myogenin antibodywas obtained fromBDPharmingen (Frank-
lin Lakes, New Jersey, USA). Anti-MHC antibody was obtained from
DSHB. Anti-CyclinD1 antibody was obtained from Abcam. Cy3-conju-
gated goat anti-mouse antibody was obtained from Jackson
ImmunoResearch Laboratories Inc. (West Grove, PA, USA). Anti-α-tubu-
lin, heparin, TSA and AraC were obtained from Sigma (Rowville, Victo-
ria, Australia). BMP4 and FGF1 were obtained from R&D systems
(Minneapolis, MN, USA). Selective soluble adenylyl cyclase inhibitor,
KH7, was obtained from Tocris Bioscience (Bristol, UK).Msx1 (Addgene
plasmid#21024) andMsx2 (Addgeneplasmid#21025) constructswere
obtained from Addgene depository (Stelnicki et al., 1997).
2.2. Mammalian cell culture
Mouse pmi28 myoblasts (Kaufmann et al., 1999) were cultured in
DMEM supplemented with 20% fetal bovine serum and 1% L-glutamine
and cultured at 37 °C in 5% CO2. Myotubes were obtained by switching
the conﬂuent myoblast cultures to a mediumwith DMEM supplement-
edwith 10% horse serumand 1% L-glutamine at 37 °C in 5% CO2 for three
days. To induceMsx1, Msx2 or GFP alone, myotube cultures were sup-
plemented with 2 μg/ml doxycycline in growth medium that was pre-
pared with doxycycline-free fetal bovine serum (Clontech, Mountain
View, CA, USA). For TSA, BMP4, FGF1 and heparin treatments, themedi-
umwas aspirated and fresh differentiationmediumwith orwithout the
factors was added on the myotube cultures.2.3. Lentivirus production and transduction
Msx1,Msx2 and GFP constructs were subcloned into pLVX-TRE3G
lentiviral vector (Clontech, Mountain View, CA, USA). Lentiviruses
were packaged in Lenti-X 293T cells (Clontech, Mountain View, CA,
USA). For the expression of doxycycline-dependent transactivator,
lentiviruses containing pLVX-Tet3G vector were produced. Pmi28
myoblasts were then transduced with two lentiviral stocks simulta-
neously in a ratio of 1:1. Double-transduced myoblasts were selected
under the pressure of Puromycin (for pLVX-TRE3G) and G418 (for
pLVX-Tet3G), expanded and frozen.
2.4. Myotube isolation
3-day-old heterogeneous myotube cultures of pmi28 line were
gently washed with PBS and incubated in a pre-warmed StemPro
Accutase dissociation reagent (Invitrogen, Carlsbad, CA, USA) for
10 °min at 37 °C. The cell suspension was ﬁltered with a 40 mm
nylon ﬁlter mesh (BD Falcon, Franklin Lakes, New Jersey, USA). The
ﬁlter was washed with a differentiation medium several times to
wash off the mononucleated cells. Myotubes that are trapped on
the mesh were retrieved and recultured on gelatin-coated culture
dishes in a differentiation medium containing 25 mM AraC. After
three days, the medium was replaced with fresh differentiation
medium to get rid of AraC before the treatments were initiated.
2.5. Western blots
Treated pmi28 myotube cultures were washed with PBS and lysed
in a SDS-RIPA buffer supplemented with protease inhibitors (cOmplete
Proteinase Inhibitor, Roche, Basel, Switzerland) and benzonase
(Novagen, Darmstadt, Germany). Lysates were cleared by a centrifuga-
tion at 13 k rpm for 10 min. Total protein was measured by BCA
(Pierce, Waltham, MA, USA). Equal amounts of total protein were sep-
arated on 5%–15% gradient SDS-PAGE gels, transferred to nitrocellulose
membranes and immunoblotted for anti-myogenin (1:100), anti-MHC
(1:200) and anti-α-tubulin (1:5000).
2.6. Live cell imaging
Isolated transgenic pmi28 myotubes were treated with 2 μg/ml
doxycycline in growth medium. Over the course of next four days,
phase contrast images were acquired from live myotube cultures
using a 5× phase-contrast objective, an AxioCamHRm camera (res-
olution of 1388 × 1040 pixels) with a Zeiss AxioObserver Z.1 and
the AxioVision software. Individual pictures were saved as
compressed, but lossless PNGs. Cells were observed using self-pro-
grammed software. Quantiﬁcation of cleavage was done by
analyzing time-course image series for each condition and
manually assigning cleavage events to individual myotubes.
2.7. RNA extraction, reverse transcription and quantitative real time poly-
merase chain reaction (qRT-PCR)
Total RNA was extracted with TRIzol (Invitrogen, Carlsbad, CA, USA),
DNase-treated with TURBO™ DNase (Ambion, Life Technologies, Wal-
tham, MA, USA) and reverse-transcribed into ﬁrst strand cDNA
(Thermo Scientiﬁc, Waltham, MA, USA). The qRT-PCR reactions were
run in LightCycler 96 (Roche Applied Science, Basel, Switzerland). Rela-
tive quantiﬁcation was performed. Expression of each gene was nor-
malized to 18S rRNA expression. The primer sequences used in
qRT-PCR reactions were as follows: 5′- AGGAGTGGGCCTGCGGCTTA -3′
and 5′- AACGGCCATGCACCACCACC -3′ for mouse 18S rRNA; 5′-
GAGTTCTCCAGCTCGCTCAG -3′ and 5′- CTTCAGCTTCTCCAGCTCCG-3′ for
mouse Msx1; 5′- AAAGGCGGTGACTTGTTTTCG -3′ and 5′- CCTTGAT-
CCTGCGCTCCTCT-3′ for mouseMsx2; 5′- TGAAGAGCCGAGAGGTTCAC -
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TGAGGGTGCGGATTTCCTG -3′ and 5′- CACGTTTGCTCCTCCTTCCT -3′ for
mouse Mrf4; 5′- CTCCTGTGCTGATGATACCG -3′ and 5′- ATTGGCAAAA-
CCACACAATG -3′ for mouse Myogenin; 5′- GTGGGTCCACGGAATCTG -3′
and 5′- CACATGTCTGTGCTGGGAAG -3′ for mouse CyclinD1; 5′-
TTGGGTCACTGGGACTCTGA -3′ and 5′- TTGGAGCCAGAGAAGAACCC-3′
for mouse CyclinA; 5′- GTCTTCCAGCCCATTGAACC -3′ and 5′- ACGGAAC-
TAAGAGGAGCAGC -3′ formouse Ptgs2; 5′- TCCTCTCTGTTGCGTGTGTC -3′
and 5′- CGTTAAGCAACAGGACATGC -3′ for mouse Ptger4; 5′-
AACCGCAACTAGAGACCTGC -3′ and 5′- AAACCTGTTGGGGTCAAGGG -3′
for mouse Pax7; 5′- AAGACGGTCTCATAGCCCAG -3′ and 5′- TTCCCAG-
CACCTAAGGAGTG -3′ for mouse Fgf4; 5′- AAGCATTAAGGCCTTGGCAC -
3′ and 5′- TGAAGTCCCAAGGCCTCTAG -3′ for mouse Fgfr4.2.8. Transcriptome sequencing and data analysis
RNA was extracted with TRIzol (Invitrogen, Carlsbad, CA, USA),
DNase-treated with TURBO™ DNase (Ambion, Life Technologies, Wal-
tham, MA, USA), reverse-transcribed and sequenced using Illumina
Hi-Seq. Transcripts were aligned with TopHat 2.0 (Kim et al., 2013),
and differential expression analysis was performed using the edgeR
package (Robinson et al., 2010) in R (R Development Core Team,
2010). A gene was considered differentially expressed if its absolute
fold changewas greater or equal to 1.5 and its Benjamini–Hochberg-ad-
justed (Benjamini andHochberg, 1995) p-valuewas less than 0.01, such
that the false discovery rate (FDR) was controlled at 1%. Gene Ontology
(GO) analysis was performed using the DAVID database (Dennis-Jr et
al., 2003).2.9. Immunocytochemistry
Isolated pmi28 myotubes were cultured on gelatin-coated 8-well
chamber slides (Nunc Lab-Tek, Waltham, MA, USA). After treatment,
myotubes were washed with PBS, ﬁxed in 2% PFA for 15 min, perme-
abilized with PBS-Triton 0.2% for 10 min and blocked with 1% BSA in
PBS-Triton 0.2% for 10 min. Myotubes were incubated with anti-
CyclinD1 antibody (1:100) and then with Cy3-conjugated goat anti-
mouse IgG (1:1000) in a blocking solution for 1 h at room temperature
in a humidiﬁed chamber. Cells were stained with DAPI (2 ng/ml in 1%
BSA in PBS-Triton 0.2%) and then methanol ﬁxed at−20 °C for 5 min.
Fluorescent images were taken using a Nikon ﬂuorescent microscope
at 40× magniﬁcation.2.10. EdU staining
Isolated pmi28 myotubes were cultured on gelatin-coated 8-well
chamber slides (Nunc Lab-Tek, Waltham, MA, USA). After three days
of doxycycline treatment in a growth medium, EdU was added into
the doxycycline-containing medium for 24 h. Myotubes were then
quickly washed with PBS, ﬁxed in 2% PFA for 15 min, blocked with 3%
BSA in PBS and permeabilized with 0.5% Triton for 20 min. Click-iT
chemistry was performed on permeabilized myotubes according to
manufacturer's protocol (Invitrogen, Carlsbad, CA, USA). Cells were
then stained with DAPI. Fluorescent images were taken using a Nikon
ﬂuorescent microscope at 40× magniﬁcation.2.11. Statistical analysis
The average values of biological replicates are given as the mean ±
SEM. Signiﬁcance testing for qRT-PCR analyses and the quantiﬁcation
of myotube cellularization was performed with Student's t-test. Signiﬁ-
cancewas deﬁned as p b 0.05with the convention ‘***’ for p b 0.0001, ‘**’
for p b 0.01, and ‘*’ for p b 0.05.3. Results
3.1. MSX2 downregulates expression of myotube markers
In order to test the potency of MSX2 in dedifferentiation, we gener-
ated doxycycline-inducible cell lines expressing Msx1 or Msx2 along
with GFP or GFP alone. Fig. 1A shows the ectopic constructs that were
packaged into lentiviral vectors and transduced into the myogenic cell
line, pmi28 (Kaufmann et al., 1999). pmi28 myoblasts can be cultured
until conﬂuence and differentiated into heterogeneous cultures of mul-
tinucleated myotubes and undifferentiated mononucleates. When the
transgenic myoblast lines were differentiated and induced with 2 μg/
ml doxycycline for three days, bothMsx1 andMsx2 transcript levels in-
creased by 130- and 90-fold, respectively (Fig. S1A). The induction was
also conﬁrmed at the protein level for both proteins (Fig. S1B).
One hallmark of dedifferentiation seen in newt muscle cells is the
loss of muscle markers, also known as phenotypic dedifferentiation
(Duckmanton et al., 2005). Therefore, we asked if MSX1 and MSX2 led
to the loss of muscle differentiation markers. Myosin heavy chain
(MHC) is a well-characterized late differentiation marker for muscle
cells (Bentzinger et al., 2012). Fig. 1B shows thatMHC transcript levels
are decreased by 80% uponMsx2 expression for three days in heteroge-
neous myotube cultures. On the other hand, MHC transcript levels did
not change inMsx1 and GFP-alone expressing cultures, distinguishing
the potencies of MSX1 and MSX2 in inducing phenotypic dedifferentia-
tion in mammalian myotubes. We next asked if MSX2 was able to
downregulate other prominentmyotube markers. MRF4 andmyogenin
are twomyogenic regulatory factors that are crucial for myotube differ-
entiation (Bentzinger et al., 2012).Mrf4 and myogenin transcript levels
decreased upon Msx2 expression by 90% and 30%, respectively (Fig. 1
C–D). Msx1 expression led to a signiﬁcant decrease (by 80%) only at
Mrf4 transcript levels (Fig. 1C). The levels of both transcripts did not
change in GFP-expressing control cultures (Fig. 1 C–D). The expression
changes induced by MSX2 were also reﬂected at the protein levels.
MHC and myogenin protein levels were decreased upon three days of
Msx2 expression in myotube cultures (Fig. S2A). In contrast, levels of
both proteins did not change in control GFPmyotubes (Fig. S2A). To en-
sure that ourMsx1 construct was functional, we tested its potential for
MSX1's previously characterized function to inhibit myoblast differenti-
ation into myotubes (Wang et al., 2011). When overexpressed in myo-
blasts that are switched to differentiation conditions, both Msx1 and
Msx2 led to smaller and fewer MHC-positive myotubes compared
with their uninduced controls and the GFP control. Therefore, our
Msx1 construct inhibited differentiation as reported previously (Fig.
S3). Consistent with the speciﬁcity of the responses uponMsx2 expres-
sion,Mrf4 transcript levels showed a dose–response curve for different
levels of MSX2 (Fig. S4 1A–B). We also measured CyclinD1 transcript
levels, a cell cycle regulator whose expression is upregulated by MSX1
and MSX2 (Hu et al., 2001) and saw a similar dose–response curve
upon different levels of Msx2 induction (Fig. S4C), indicating that
MSX2 concentration is a key determinant for its downstream effects.
We considered the possibility that the transcript responses seen in
heterogeneous cultures were in part due to remaining mononucleated
cells. To control for such effects, we isolated myotubes and recultured
them in the presence of the anti-metabolic drug arabinofuranosyl cyti-
dine (AraC), which kills the remaining proliferating mononucleated
cells by interfering with DNA synthesis (Fig. S2B)
(Mastroyiannopoulos et al., 2012). In these isolated, highly pure
myotube cultures we measured the transcript levels ofMHC andMrf4
upon MSX2, MSX1 or GFP-alone induction over the course of three
days. As shown in Fig. S2 C–D, MHC and Mrf4 transcript levels went
down after one day and continued to decrease by N90% after three
days of Msx2 expression. In parallel to what we observed in
heterogeneous cultures,Msx1 expression did not changeMHC transcript
levels and had a more modest effect onMrf4 levels compared with that
of Msx2 expression. No change was detected in GFP-expressing
Fig. 1. Ectopic Msx2 expression downregulates expression of muscle differentiation
markers. A. Schematic representation of lentiviral constructs used for the generation of in-
ducible myoblast lines. Doxycycline-inducible promoter is followed by either Msx1 or
Msx2 or none.GFPwas cloned in 3′ end of an IRES element. (B-D).Msx2downregulates ex-
pression of MHC (B), Mrf4 (C) and myogenin (D) in myotubes. Heterogeneous myotube
cultures were induced with doxycycline for three days. Transcript levels were measured
by qRT-PCR. Note that ectopic Msx1 expression downregulates only Mrf4 expression.
Data are representative of three independent experiments and are represented as
means ± SEM (***p b 0.0001; **p b 0.01; *p b 0.05; ns, not signiﬁcant versus untreated
conditions).
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S2 C–D). Taken together, MSX2 downregulates transcript and protein
levels of myotube markers.
3.2. MSX2 reprograms myotube nuclei
To extensively characterize transcriptome-wide gene expression
upon ectopic Msx2 expression in myotubes, we performed RNA se-
quencing (RNA-seq) on uninduced and induced isolated myotubes car-
ryingMsx2 and GFP or GFP alone expression cassettes. As a reference for
the undifferentiated state, we also sequenced the transcriptomes of
uninducedmyoblasts carrying these two transgenic constructs. To min-
imize the potential cell-to-cell variation in response to long-termMsx2
expression, we focused on a relatively early time point and induced
the isolated myotube cultures for one day. First, we identiﬁed 4964 up-
regulated and 4464 downregulated transcripts in myotubes compared
with myoblasts (uninduced GFP control cells; ≥1.5-fold change; FDR
corrected p-values b 0.01) (Fig. 2 A–B). Upon ectopicMsx2 expression
in myotubes, 923 transcripts were downregulated, whereas 1283 tran-
scripts were upregulated (Fig. 2 A–B). Based on the potential role of
MSX2 in dedifferentiation, we reasoned that the transcripts that are
normally upregulated in myotubes in comparison with myoblasts
should be downregulated upon Msx2 expression. In accord with this
idea, 575 myotube-enriched transcripts were downregulated after one
day ofMsx2 expression (Fig. 2A). Similarly, 331myoblast-enriched tran-
scripts were upregulated upon Msx2 expression (Fig. 2B). A heat map
generated for these latter 906 genes in total shows that there are clear
differences between expression proﬁles of myoblasts and myotubes in-
dependent of their transgenic background. Induction of Msx2 expres-
sion in myotubes reverses myotube expression proﬁle towards the
myoblast proﬁle (Fig. 2C). A principal component analysis (PCA) done
for the same transcript set across samples also conﬁrmed this result
(Fig. S5 A–B). It demonstrated a clear separation between myoblast
and myotube samples and showed that the expression proﬁles of
Msx2-expressing myotubes are more similar to those of the myoblast
samples. We then performed gene ontology (GO) enrichment analysis
for the transcripts regulated by Msx2 expression in myotubes. As sug-
gested by the phenotypic dedifferentiation induced byMsx2 expression,
downregulated transcripts were enriched in GO terms related tomuscle
tissue development and differentiated muscle structures (Table S1). On
the other hand, upregulated transcripts were enriched in GO terms re-
lated to signaling, extracellular matrix and transcription (Table S2).
We next validated selected transcript hits from the RNA-seq analysis
by qRT-PCR. As shown in Fig. 2D, transcript levels of myotube marker
Mrf4 decrease by ~80% uponMSX2 induction, whereas they remain un-
changed by the expression of GFP alone. Furthermore, transcript levels
of the myoblast marker Pax7 increase by ~3.5-fold upon MSX2 induc-
tion, as opposed to no change by GFP alone. We also validated several
other transcript responses, whichwere shown to have a role in regener-
ation blastema in salamanders and zebraﬁsh or inmuscle differentiation
pathways (Ferretti et al., 2001; Poss et al., 2000). Two Fgf pathway
members, FGF4 and FGFR4, which are upregulated in regeneration blas-
tema in animals were also upregulated upon Msx2 expression by 11-
and 3-fold, respectively. The prostaglandin pathway has a prominent
role inmyoblast fusion (Horsley and Pavlath, 2003; Zalin, 1977). Prosta-
glandin E (PGE) has been shown to positively regulate myoblast fusion
(Entwistle et al., 1986; David and Higginbotham, 1981; Bondesen et al.,
2006). Two members of the prostaglandin pathway, namely Ptgs2 and
Ptger4, were downregulated in the RNA-seq analysis. Ptgs2 encodes for
COX2 enzyme, which is the most critical enzyme in the prostaglandin
pathway (Bondesen et al., 2006). Ptger4, on the other hand, is a PGE
receptor (Yokoyama et al., 2013). We validated the transcript decrease
for Ptger4 by qRT-PCR and showed that there was a non-signiﬁcant
trend towards a decrease for Ptgs2 transcripts after one day of msx2
induction (Fig. 2 H-J). Given the role of prostaglandin pathway in
myoblast fusion, we reasoned that this pathway might need to be
Fig. 2. Ectopic Msx2 expression reprograms myotube nuclei. A. Myotube-enriched transcripts are downregulated upon Msx2 expression. The number of upregulated transcripts in
myotubes vs. myoblasts is shown in a Venn diagram as myotube-enriched transcripts (blue disk) and was compared with downregulated transcripts by MSX2 (red disk). Data are rep-
resentative of three independent experiments. A false discovery rate (FDR)-corrected p-value of less than 0.01 and an at least 1.5-fold expression change were used as selection criteria
to call genes differentially expressed between samples. B.Myoblast-enriched transcripts are upregulated uponMsx2 expression. The number of downregulated transcripts inmyotubes vs.
myoblasts is shown in a Venn diagram as myoblast-enriched transcripts (blue disk) and was compared with upregulated transcripts by MSX2 (red disk). C.Msx2-expressing myotubes
have a similar expression pattern to undifferentiated myoblasts. The displayed heatmap was generated for a total of 906 transcripts in the Venn diagram overlaps in A. and B. (D–G) Val-
idation of RNA-seq results. Transcript levels ofMrf4 (D), Pax7 (E), Fgf4 (F), Fgfr4 (G), Ptgs2 (H) and Ptger4 (J) weremeasured by qRT-PCR uponMsx2 expression for one day. Data are rep-
resentative of three independent experiments and are represented as means ± SEM (***p b 0.0001; **p b 0.01; *p b 0.05; ns, not signiﬁcant versus untreated conditions). (I, K) Selective
downregulation of prostaglandinpathwaybyMSX2.Msx2was expressed in isolatedmyotube cultures up to 3 days. Transcript levels of Ptgs2 (I) and Ptger4 (K)weremeasured by qRT-PCR.
Data are representative of three independent experiments and are represented as means ± SEM (***p b 0.0001; **p b 0.01; *p b 0.05; ns, not signiﬁcant versus untreated conditions).
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fusion. Therefore, we also measured transcript levels of Ptgs2 and
Ptger4 for later time points. As shown in Fig. 2I, after two and three
days of Msx2 expression, Ptgs2 transcript levels went down by 60–
80%. Similarly, Ptger4 transcript levels were downregulated by ~80%
upon Msx2 expression (Fig. 2K). GFP expression alone did not change
transcript levels of both genes (Fig. 2 I–K). Surprisingly,Msx1 expression
in myotubes also did not lead to any decrease in Ptgs2 and Ptger4, sug-
gesting that these two transcripts were selectively downregulated by
MSX2. Taken together, these results conﬁrm the RNA-seq results and
demonstrate that MSX2 reprograms the myotube transcriptome to
become more similar to the myoblast transcriptome.Fig. 3. EctopicMsx2 expression leads to signiﬁcant morphological changes and cellularization i
myotubes. Isolated transgenic myotubes were induced with doxycycline and imaged for 4 da
cells. Note that Msx1 and GFP-alone expressing myotubes do not undergo cellularization. B.
Msx1,Msx2 or GFP alone expression were quantiﬁed. Total number of myotubes analyzed for ea
(373);Msx2-induced (334); GFP-uninduced (350); GFP-induced (351). Data are representative
**p b 0.01; *p b 0.05; ns, not signiﬁcant versus untreated conditions). C. Inhibition of soluble ad
ducedwith doxycycline in the presence or absenceof a selective inhibitor for solubleAdenylyl cy
quantiﬁed. Total number ofmyotubes analyzed for each condition is as follows:Msx2-uninduced
(212). Data are representative of three independent experiments and are represented asmeans3.3.MSX2, but notMSX1, drivesmajor cellularization events inmammalian
myotubes through a cAMP pathway
A number of top-ranked downregulated transcripts in our RNA-seq
results encode structural proteins for muscle cells (Table S3). Selective
downregulation of structural proteins and the prostaglandin pathway
prompted us to assess whether these gene expression differences
would be reﬂected in a change of morphology of myotubes. Since
cellularization is one of the hallmarks of muscle cell dedifferentiation
during newt regeneration, we aimed to analyze potential cleavage
events in isolated myotube cultures by live cell imaging (Brockes and
Kumar, 2002). Fig. 3A shows that myotubes induced to ectopicallyn mammalian myotubes through cAMP pathway. A.Msx2 expression leads to cleavage of
ys. Black arrow shows a myotube that undergoes cleavage. Red arrows mark the cleaved
Msx2-induced cleavage is seen in nearly half of the myotubes. Cleaved myotubes upon
ch condition is as follows:Msx1-uninduced (386);Msx1-induced (355);Msx2-uninduced
of three independent experiments and are represented as means ± SEM (***p b 0.0001;
enylyl cyclase blocks MSX2-induced cellularization. Isolated transgenic myotubes were in-
clase (KH7, 100 μM)and imaged for 4 days. Cleavedmyotubes uponMsx2 expressionwere
(196);Msx2-induced (212);Msx2-induced+100 μMKH7 (224);Msx2-induced+DMSO
±SEM(***p b 0.0001; **p b 0.01; *pb 0.05; ns, not signiﬁcant versus untreated conditions).
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S1). Quantiﬁcation of the number of cleaved myotubes revealed that
nearly 50% ofMsx2-expressingmyotubes cleave into smaller fragments
(Fig. 3B). To our surprise,Msx1-expressing myotubes did not show sig-
niﬁcant numbers of cleavage events (Fig. 3 A–B). As expected, GFP-ex-
pressing control myotubes did not result in signiﬁcant numbers of
cleavage events. Hence,Msx2 is amajor driver of cellularization inmam-
malian myotubes.
Among the highest upregulated transcripts in our RNA-seq analysis
we noticed several G-protein coupled receptors (GPCRs), such as the
corticotropin-releasing hormone receptor 2 (Crhr2). GPCRs can activate
cAMP signaling among others. This downstream secondary messenger
signaling has various crucial roles in muscle physiology, including
those during myoblast differentiation and fusion (Berdeaux and
Stewart, 2012). Therefore,we reasoned that cAMPpathway couldmedi-
ate MSX2-induced changes in myotubes, including cellularization and
phenotypic dedifferentiation, and inhibition of this pathway would
block the morphological and gene expression changes upon MSX2. To
test this, we used a selective inhibitor for soluble adenylyl cyclase,
KH7. When the myotubes were treated with KH7 during ectopicMsx2
expression, myotube cellularization was blocked and returned to base-
line levels (Fig. 3C). Furthermore, KH7 treatment during ectopic Msx2
expression also reversed the increase in the transcript levels of themyo-
blast marker Pax7 (Fig. S6B) and the cell cycle regulator CyclinD1 (Fig.
S6C). The decrease in the levels of Ptger4 upon MSX2 was also reversed
by KH7 (Fig. S6D). Thus, we conclude that cAMP signaling is necessary
for the MSX2-induced cellularization and the phenotypic dedifferentia-
tion of mammalian myotubes.3.4. MSX2 leads the myotube nuclei into partial cell cycle re-entry
Besides morphological changes and downregulation of muscle-spe-
ciﬁc markers, myotube dedifferentiation also entails cell cycle re-entry
of postmitotic myotubes (Duckmanton et al., 2005). Therefore, we
wanted to assess the potential of Msx2 expression in inducing cell
cycle re-entry and compare it with that ofMsx1 expression. One of the
main roadblocks for cell cycle re-entry in mammalian myotubes has
been shown to be CyclinD1 expression, which drives the myotubes
from G0 to G1 (Latella et al., 2001). Our results in Fig. S4C and S6C
showed that Msx2 expression upregulates CyclinD1 transcript levels.
We then analyzed CyclinD1 protein and transcript levels in isolated
myotube cultures after Msx2, Msx1 and GFP-alone expression. As
shown in Fig. 4A, Msx2 expression upregulated CyclinD1 transcript
levels around 5.5-fold, as opposed to no change upon GFP expression
alone. Msx1 expression also had a more modest effect and increased
the CyclinD1 transcript levels by about 3-fold (Fig. 4A). We then immu-
nostained myotubes for CyclinD1. While CyclinD1 was not detected in
untreated Msx2-, Msx1- or GFPmyotubes, Msx2-expressing myotubes
were positive for nuclear CyclinD1 (Fig. 4B, arrows). As indicated by
the transcript levels, Msx1 expression led to somewhat less upregula-
tion of CyclinD1 compared with levels induced by MSX2. As expected,
control GFP expression did not change CyclinD1 levels.
Next, we testedwhetherMsx2- andMsx1-expressingmyotubes pro-
ceed to S-phase and initiate DNA replication. Cyclin A is one of thewell-
characterized markers for S-phase entry and is not expressed in
myotubes (Yoshida et al., 1998). Therefore, we ﬁrst checked Cyclin A
transcript levels upon Msx2, Msx1 and GFP-alone expression for two
and three days. Fig. S7A demonstrates that Cyclin A levels remained un-
changed for three days upon MSX2 or MSX1 induction. We then tested
DNA replication after four days of Msx2 and Msx1 expression in
myotubes by EdU-incorporation assay. None of themyotube-associated
nuclei was positive for EdU staining, indicating that myotube nuclei did
not replicate their DNA (Fig. S7B, arrows). Together, we conclude that
Msx2 expression leads to a partial cell cycle re-entry, judged by the in-
crease in CyclinD1 levels and failure to enter S-phase.3.5. MSX2-induced myotube dedifferentiation can be recapitulated
pharmacologically
Dedifferentiation protocols that will be ultimately used for thera-
peutic purposes would preferably be induced pharmacologically. Even
though most signaling pathways are shared between salamanders and
mammals, mammalian myotubes are known to be refractory to soluble
factors that induce dedifferentiation in newtmyotubes orwithin blaste-
ma (Yun et al., 2014). We reasoned that this refractory nature could be
partially caused by chromatin features in mammalian cells. If the chro-
matin would be made more accessible, the same soluble factors could
trigger similar responses in mammalian cells. To test this hypothesis,
we took a candidate approach and chosemolecules that would upregu-
late Msx2 expression and are implicated to have a role in blastema.
Trichostatin A (TSA), a histone deacetylase (HDAC) inhibitor, and
bone morphogenic protein 4 (BMP4) have been shown to upregulate
MSX proteins (Mehra-Chaudhary et al., 2001; Wang et al., 2010;
Binato et al., 2006). Fibroblast growth factor 1 (FGF1), on the other
hand, has anti-apoptotic effects and induces partial dedifferentiation
in adultmammalian cardiomyocytes (Engel et al., 2005). Non-transgen-
ic heterogeneous myotube cultures of pmi28 line were treated with
TSA, BMP4, FGF1 alone and their combinations for 24 h. As shown in
Fig. S8A-B,Msx1 and Msx2 transcript levels increased by ~3- and ~17-
fold, respectively, upon combinatorial treatment with TSA, BMP4 and
FGF1 (TBF). Next, we checked the expression of two myotube markers
upon different treatments. Transcript levels ofMHC andMrf4 decreased
by N90% and N80% upon TBF treatment, respectively (Fig. S8C-D). Inter-
estingly, TBF treatment resulted in the maximum downregulation
among the conditions tested.We also compared the CyclinD1 transcript
levels across different combinatorial treatments. CyclinD1wasmost up-
regulated by FGF1 alone (~12-fold) and BMP4-FGF1 combination (~13-
fold). TBF treatment led to an ~5-fold increase in CyclinD1 transcript
levels (Fig. S8E). Western blot analysis demonstrated that TBF treat-
ment downregulated protein levels of myotube markers, MHC and
myogenin, in heterogeneous myotube cultures (Fig. S8F).
We next aimed to test the potential of TBF treatment to induce
cellularization in myotubes. To test this, we isolated myotube cultures
of pmi28 line and performed live imaging upon TBF treatment. Fig. 5A
shows a TBF-treated multinucleated myotube that undergoes two con-
secutive cleavage events within the course of 4 days (black arrow), as
opposed to no such morphological change in the control myotube. We
also sought to conﬁrm the TBF-induced expression changes seen in het-
erogeneousmyotube cultures in isolatedmyotube cultures. As shown in
Fig. 5B, TBF treatment increased the transcript levels ofMsx1 andMsx2
in isolated myotube cultures by ~6- and ~15-fold, respectively. In ac-
cord with the response seen in heterogeneous myotube cultures, the
myotube markers MHC and Mrf4 were decreased by 50% in isolated
myotube cultures treated with TBF for 24 h (Fig. 5C). Finally, we tested
whether the CyclinD1 increase observed in heterogeneous cultures was
a myotube response. Isolated and TBF-treated myotube cultures were
immunostained for CyclinD1. TBF treatment increased CyclinD1 levels
in myotube-associated nuclei (Fig. 5D, arrow). About 90% of the TBF-
treatedmyotube-associated nucleiwere positive for CyclinD1. Taken to-
gether, the pharmacological treatment increases the expression ofMsx
genes and recapitulates several aspects ofmyotube dedifferentiation in-
duced by ectopic expression ofMsx2.4. Discussion
In this study we have shown that ectopic expression of a mammalian
ortholog of the early amphibian blastema marker, MSX2, leads to dedif-
ferentiation of mammalian myotubes with partial cell cycle re-entry.
We propose a model in which MSX2 1) reprograms myotube nuclei by
downregulating myotube-speciﬁc transcripts and upregulating progeni-
tor myoblast-speciﬁc transcripts, 2) leads to cellularization of myotubes
Fig. 4. Partial cell cycle re-entry by MSX2. A. CyclinD1 transcript levels are upregulated uponMsx2 andMsx1 expression. Transcript levels of CyclinD1were measured by qRT-PCR upon
Msx1, Msx2 and GFP alone expression for one day. Data are representative of three independent experiments and are represented as means ± SEM (***p b 0.0001; **p b 0.01;
*p b 0.05; ns, not signiﬁcant versus untreated conditions) B.Msx2 and Msx1 expression increases the protein levels of CyclinD1. Isolated myotubes were induced with doxycycline for
three days and immunostained for CyclinD1. White arrows point to myotubes with CyclinD1-positive nuclei. Arrowhead points to a contaminating mononucleated myoblast. Data are
representative of three independent experiments.
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regulating CyclinD1 (Fig. 6).
Our results demonstrate that ectopicMsx2 expression in mammali-
anmyotubes leads to substantial morphological changes and eventuallyto the cleavage of nearly half of themyotubes into smaller cells. Howev-
er, we did not observe proliferation of amononucleated cleaved cell and
colony formation. This indicates that cellularization is independent of
cell cycle re-entry and that additional pathways need to be activated
Fig. 5.A pharmacological treatment that recapitulatesMSX2-induced dedifferentiation. A. TSA–BMP4–FGF1 (TBF) treatment leads to cleavage of myotubes. Isolatedmyotubeswere treat-
edwith TBF (60 ng/ml TSA, 25 ng/ml BMP4 and 50 ng/ml FGF1 (in combinationwith 10 ng/ml heparin)) and imaged for 4 days. Black arrows show amyotube that undergoes two rounds
of cleavage. Red arrows mark the cleaved cells. B.Msx1 andMsx2 transcript levels are increased upon TBF treatment. Transcript levels ofMsx1 andMsx2 were measured by qRT-PCR in
isolated myotubes treated with TBF for 24 h. Data are representative of six independent experiments and are represented as means ± SEM (***p b 0.0001; **p b 0.01; *p b 0.05; ns,
not signiﬁcant versus untreated conditions) C.MHC andMrf4 transcript levels are decreased upon TBF treatment. Transcript levels ofMHC andMrf4weremeasured by qRT-PCR in isolated
myotubes treated with TBF for 24 h. Data are representative of six (MHC) and four (Mrf4) independent experiments and are represented as means ± SEM (***p b 0.0001; **p b 0.01;
*p b 0.05; ns, not signiﬁcant versus untreated conditions) D. TBF treatment increases CyclinD1 protein levels. Isolated myotubes were treated with TBF for 24 h and immunostained for
CyclinD1. White arrow points to a myotube with CyclinD1-positive nuclei. Arrowhead points to a control myotube with CyclinD1-negative nuclei. Data are representative of three inde-
pendent experiments. E. Quantiﬁcation of CyclinD1 increase in myotubes. Data are from three independent experiments with a total of 414 control and 860 TBF-treated myotube nuclei
analyzed.
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MSX1 did not lead to a signiﬁcant number of cleavage events. Two pre-
vious studies that ectopically expressedMsx1 in mammalian myotubes
reported cleavage percentages of 9% and 1–5% in C2C12 myotubes and
primary mouse myotubes, respectively (Odelberg et al., 2000; Yang et
al., 2014). These studies also reported proliferation and colony forma-
tion of mononucleated cleaved cells. However, in 355Msx1-expressing
myotubes that we analyzed up until 7 days of imaging, we did not see
any cleaved mononucleated cell that initiated proliferation and formed
a colony. It is unclear whether the discrepancy between our study and
the previous ones is due to different culture models or experimental
artifacts such as contaminating mononucleated cells adjacent to
myotubes, as any remaining mononucleated cell in the culture has the
potential to form a colony. However, these differences underpin the
necessity to further assess both qualitative and quantitative
contributions of MSX1 and MSX2 in induced mammalian myotube
dedifferentiation.The ﬁnding that MHC and myogenin expression does not change
upon ectopicMsx1 expression but decreases drastically uponMsx2 ex-
pression is another piece of evidence for the selective role of MSX2 in
dedifferentiation. The previous two studies on MSX1 induction in
myotubes did not characterize MHC levels uponMsx1 expression. Our
expression data show that Mrf4 expression is signiﬁcantly decreased
by MSX1, suggesting that the extent of dedifferentiation-related events
induced byMSX1 could bemore limited thanMSX2-induced changes in
myotubes.
Myogenin expression was shown to be an early event during myo-
blast differentiation before cell cycle withdrawal and fusion (Andrés
and Walsh, 1996). The early-established expression of myogenin was
downregulated after other myotube markers such as MHC and MRF4
and right before cellularization, indicating that this myogenic factor
serves as a gatekeeper for differentiation (Andrés and Walsh, 1996).
Our results provide insights into the temporal order of events during
myotube dedifferentiation and suggest that the loss of muscle markers
Fig. 6.Model forMSX2-induced or pharmacologically inducedmammalianmuscle cell de-
differentiation. Ectopic expression ofMsx2 or TBF treatment inmammalianmyotubes lead
to 1) downregulation of myotube-speciﬁc transcripts and an upregulation of myoblast-
speciﬁc transcripts (phenotypic dedifferentiation); 2) cleavage of the myotubes into
smaller cellular fragments through cAMP pathway (cellularization) and ﬁnally 3) upregu-
lation of CyclinD1 (partial cell cycle re-entry).
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day after MSX2 induction and their expression decreases gradually in
the following days. On the other hand, we have not seen downregula-
tion of myogenin until after three days ofMsx2 expression, suggesting
that this effect is rather secondary of MSX2 transcription factor activity.
Theﬁnding thatmyogenin downregulation precedes cellularization also
suggests that dedifferentiation is not the exact reversal of differentia-
tion, but rather has its own speciﬁc sequence of events.
Our transcriptome-wide characterization of MSX2-induced changes
in myotubes demonstrates that the expression of keymyotube markers
is decreased by MSX2. We identiﬁed hundreds of myotube-enriched
transcripts that were downregulated by MSX2. It is worthwhile to
note that RNA-seq analysis was done on myotubes that expressed
Msx2 for one day. Our results showing gradual decreases in MHC and
MRF4 would suggest that the transcriptome-wide changes are likely
to happen gradually and more myotube markers are expected to be
downregulated in the later time points. A previous study showed that
BMP-inducedMSX1 orMSX2 inhibits smoothmuscle gene transcription
(Hayashi et al., 2006). Taken togetherwith our data inmyotubes of skel-
etal muscle origin, this suggests that MSX2 acts on very distinct muscle
types in a similar fashion and leads to loss of differentiated muscle
markers. Similar activities across distinct muscle types also opens up
the possibility that MSX2 can lead to dedifferentiation of cardiacmuscle
to a progenitor state.
Our transcriptome analysis further identiﬁed activated and inhibited
signaling pathways during myotube dedifferentiation. These pathways
not only include those that were implicated to have roles in salamander
regeneration, such as FGF pathway (Ferretti et al., 2001), but also those
that were not studied within the context of dedifferentiation, such as
prostaglandin pathway. Fgfr4 transcriptswere shown to be upregulated
following tail amputation in newts (Ferretti et al., 2001). Similarly, FGF4
was shown to induce a regenerative response in wing bud regeneration
in chick embryos (Kostakopoulou et al., 1996). Upregulation of both of
these FGF pathway members uponMsx2 expression suggests that they
might also play a role during myotube dedifferentiation. On the other
hand, two crucial members of prostaglandin pathway, namely the
enzyme COX2 and the prostaglandin receptor PTGER4 are
downregulated. Interestingly, Msx1 expression in myotubes does not
downregulate transcript levels of these prostaglandin pathway
members. Myoblast fusion that leads to formation of multinucleated
myotubes is regulated by prostaglandin E (PGE) (Zalin, 1977;
Entwistle et al., 1986; David and Higginbotham, 1981). COX2 enzyme
is responsible for PGE production and PTGER4 is a receptor for PGE.
Interestingly, we found that downregulation of the PGE-synthesizing
enzyme and its receptor precedes cellularization suggesting that
downregulation of the prostaglandin pathway might be necessary for
MSX2-driven cellularization.The importance of the ﬁnding that the prostaglandin pathway is se-
lectively downregulated by MSX2, but not MSX1, is 2-fold; i) this func-
tional disparity between MSX1 and MSX2 provides a mechanistic
insight into a cellularization event during muscle dedifferentiation and
ii) it also demonstrates that these twohomeodomain-containing homo-
log proteins are not completely redundant and have different function-
alities. Previous studies and sequence comparisons have shown
differential binding afﬁnities of MSX1 and MSX2 homeodomains to
DNA and differences in primary protein sequence at the N-terminus
(Catron et al., 1996). Our results indicate that these differences lead to
functional and qualitative distinction of MSX1 and MSX2. This idea is
also strengthened by our observation thatMHC transcript levels are de-
creased only byMsx2 expression in myotubes, but not MSX1.
Our ﬁnding about the role of the cAMP pathway in myotube
cellularization and phenotypic dedifferentiation connects MSX2-in-
duced cytosolic signalingwith thenuclear changes and opens up several
questions about the downstream and parallel signaling events. Which
GPCRs are activated upon MSX2-induction and are responsible for sig-
naling to the nucleus for gene expression changes? What downstream
effectors, secondary transcription factors and epigenetic modiﬁers me-
diate this signaling? How does the role of cAMP signaling during dedif-
ferentiation compare with its role during differentiation? Previous
studies have shown that intracellular cAMP levels decrease upon myo-
blast fusion and sustained cAMP signaling inhibits myoblast fusion
and differentiation (Hu and Olson, 1988; Li et al., 1992; Tsai et al.,
1997). Our results indicate that cAMP signaling is a major regulator of
the downregulation of myotube-speciﬁc gene expression proﬁle, as
well as the consecutive morphological changes induced by ectopic
Msx2 expression.
Previous studies on newt myotubes undergoing dedifferentiation
suggested that cell cycle re-entry was uncoupled from phenotypic de-
differentiation and cellularization. (Velloso et al., 2000). Furthermore,
several reports aimed at inducing cell cycle re-entry in myotubes iden-
tiﬁed 1) CyclinD1 and CDK4 activation; 2) Rb and ARF downregulation,
or 3) sustained ERK activity as necessary events (Pajcini et al., 2010;
Latella et al., 2001; Yun et al., 2014). Our ﬁndings showing extensive
phenotypic dedifferentiation and cellularization along with partial cell
cycle re-entry suggest a similar uncoupling between the ﬁrst two and
the latter events formammalianmyotubes. On theother hand, the path-
ways leading to the events related to cell cycle re-entry are not entirely
activated during Msx2 expression, with the exception of CyclinD1
upregulation.
A recent study showed that a combination of BMPs and FGFs was suf-
ﬁcient to form the blastema in a newt limb regenerationmodel (Makanae
et al., 2014). Although this study analyzed a complex heterogeneous
tissue such as blastema, the results from our pharmacological treatments
that recapitulate phenotypic dedifferentiation and cellularization events
in isolated myotubes suggest that BMP and FGF signaling are likely to
contribute to muscle dedifferentiation within blastema, as well.
Both the genetic and the pharmacological inducers that we used to
engineer the amphibian dedifferentiation response into mammalian
myotubes have been previously implicated in the inhibition of differen-
tiation. Expression ofMsx genes have been associated with multipotent
progenitor cells and inhibition of differentiation of various mesenchy-
mal progenitor cells including the muscle progenitor cells (Hu et al.,
2001; Kodaka K et al., 2015; Takahashi et al., 2001). Similarly, BMP sig-
naling stimulates muscle progenitor cell expansion and inhibits myo-
genic differentiation (Ono et al., 2011; Shi et al., 2011). Interestingly,
Msx2 is a downstream target gene for BMP signaling (Brugger et al.,
2004). FGF signaling is also required to maintain the proliferative state
of the muscle progenitor cells and blocks differentiation (Olwin and
Rapraeger, 1992; Rando and Blau, 1994). These inhibitory functions of
MSX2, BMPs and FGFs on differentiation and their association with the
maintenance of the proliferative progenitor cells further strengthens
their potential to reverse the differentiated state of myotubes when
ectopically expressed or activated in those cells. Our single and
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cules that allow for a more accessible chromatin, as in the case of TSA,
mammalian myotubes exhibit an enhanced response to these signaling
molecules for cell fate reversal.
5. Conclusions
The data presented here demonstrate thatMSX2 induces dedifferen-
tiation with partial cell cycle re-entry in postmitotic multinucleated
mammalian muscle cells. Our pharmacological treatment recapitulates
MSX2-induced dedifferentiation and exhibits potential for future thera-
peutic protocols aiming at the generation ofmuscle stem cells after limb
injuries. One advantage of the skeletalmuscle tissue for such clinical ap-
plications is its accessibility by intramuscular injections, which circum-
vent any potential toxic effects of systemic injections. In conjunction
with the current protocol, future studies should target the question of
cell cycle re-entry in myotubes in order to achieve proliferating cleaved
cells. In summary, our study provides mechanistic insights into muscle
dedifferentiation, which will also help salamander regeneration re-
search where transcriptomic data are just starting to be produced
(Looso et al., 2013).
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.scr.2015.09.012.
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